

Immunotherapy in non-small cell lung cancer: Update and new insights

Xabier Mielgo-Rubio, Eider Azkona Uribelarrea, Laura Quintana Cortés, María Sereno Moyano

Corresponding author

Laura Quintana Cortés

Medical Oncology Department, Hospital Don Benito-Villanueva, Badajoz, Spain

Handling editor:

Michal Heger

Department of Pharmaceutics, Utrecht University, the Netherlands

Department of Pharmaceutics, Jiaying University Medical College, Zhejiang, China

Review timeline:

Received: 30 September, 2020

Editorial decision: 5 November, 2020

Revision received: 15 November, 2020

Editorial decision: 15 November, 2020

Published online: January 20, 2021

1st Editorial decision

05-Nov-2020

Ref.: Ms. No. JCTRes-D-20-00116

Immunotherapy in non-small cell lung cancer: update and new insights

Journal of Clinical and Translational Research

Dear author(s),

Reviewers have submitted their critical appraisal of your paper. The reviewers' comments are appended below. Based on their comments and evaluation by the editorial board, your work was FOUND SUITABLE FOR PUBLICATION AFTER MINOR REVISION.

The minor revision pertains to language polishing. Please inform us if you cannot do this yourself, find a native speaker who can help, or engage a paid service to contract it to a third party. Please note that we will not publish manuscripts that do not abide by academic standards in terms of language. It is a top priority that is explicitly addressed in our author guidelines.

If you decide to revise the work, please itemize the reviewers' comments and provide a point-by-point response to every comment. An exemplary rebuttal letter can be found on at <http://www.jctres.com/en/author-guidelines/> under "Manuscript preparation." Also, please use the track changes function in the original document so that the reviewers can easily verify your responses.

Your revision is due by Dec 05, 2020.

To submit a revision, go to <https://www.editorialmanager.com/jctres/> and log in as an Author. You will see a menu item call Submission Needing Revision. You will find your submission record there.

Yours sincerely,

Michal Heger
Editor-in-Chief
Journal of Clinical and Translational Research

Reviewers' comments:

Reviewer #1: The present paper reviews the interesting topic of the current role of immunotherapy in treatment of NSCLC. The paper is informative, clear and well written. Authors made an outstanding review of the studies analyzing the efficacy of immunotherapy in all settings (metastatic, locally advanced, neoadjuvant and adjuvant) and biomarkers. My recommendation is accept the manuscript after minor language polishing

Authors' response

Dear editors,

We thank the reviewers for their generous comments on our manuscript. We send a revised version of the manuscript that has been reviewed by a professional English language medical translator to polish English.

We believe that the article is now suitable for publication in Journal of Clinical and Translational Research.

Please, let us know if you need something else.

Best regards,

Xabier Mielgo Rubio
Unidad de Oncología
Hospital Universitario Fundación Alcorcón

2nd Editorial decision
15-Nov-2020

Ref.: Ms. No. JCTRes-D-20-00116R1
Immunotherapy in non-small cell lung cancer: update and new insights
Journal of Clinical and Translational Research

Dear authors,

I am pleased to inform you that your manuscript has been accepted for publication in the Journal of Clinical and Translational Research.

You will receive the proofs of your article shortly, which we kindly ask you to thoroughly review for any errors.

Thank you for submitting your work to JCTR.

Kindest regards,

Michal Heger
Editor-in-Chief
Journal of Clinical and Translational Research

Comments from the editors and reviewers: